Clinical trials: Vaso-occlusive Crisis
Sickle Cell Disease
Sleep Study in Adult Patients With Major Sickle Cell Disease With Paroxysmal Nocturnal Events
Hypothesis is that the occurrence of nocturnal Vaso-Occlusive Crisis (VOC) and priapism in adults might be related to episodes of nocturnal desaturation secondary to a sleep apnea syndrome.
- Trial name
- DREPASOM (NCT02539771)
- Testing
- Polysomnography and blood sample
- Where
- France
- Volunteers
- 114 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sickle Cell Disease, Pain
Effect of EMDR for Reduction of Pain Interference in Children With Sickle Cell Disease
Children with sickle cell disease may experience frequent painful episodes. This, together with the traumatic experiences during a hospitalization, can lead to the development of posttraumatic stress reactions.
- Conditions
- Sickle Cell Disease, Pain, Pain, Chronic Disease
- Trial name
- RELAX (NCT07001631)
- Testing
- Eye Movement Desensitization and Reprocessing (EMDR)
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Vaso-Occlusive Pain Episode in Sickle Cell Disease
Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease
The purpose of the study is to determine whether adding lidocaine to standard of care in pain management during severe vaso-occlusive crisis has an effect on the cumulative opioid consumption expressed as morphine milligram…
- Trial name
- LidoVOC (NCT07274254)
- Testing
- Lidocain, Standard of care
- Where
- 12 sites in France, Guadeloupe
- Volunteers
- 104 people
- Sponsor
- Nantes University Hospital
Sickle Cell Disease (SCD), Vaso-Occlusive Crises
Pleuropulmonary Ultrasound Imaging in Patients With Sickle Cell Disease in a Vaso-occlusive Crisis. "ECHODREP"
Introduction Sickle cell disease is the most common inherited genetic disorder in France and worldwide. Its main acute manifestation is vaso-occlusive crisis, a frequent reason for emergency department visits.
- Conditions
- Sickle Cell Disease (SCD), Vaso-Occlusive Crises, Acute Chest Syndrome
- Trial name
- ECHODREP (NCT07782489)
- Testing
- Pleuropulmonary ultrasound
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sickle Cell Anemia
Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease
OBJECTIVES: I. Assess the efficacy of poloxamer 188 in reducing the duration of painful vaso-occlusive crisis in patients with sickle cell disease. II.
- Trial name
- NCT00004408
- Testing
- poloxamer 188
- Volunteers
- 300 people
- Sponsor
- Mast Therapeutics, Inc.
Sickle Cell Disease (SCD)
Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients
The purpose of this study was to confirm and to establish appropriate dosing and to evaluate the safety in pediatric participants ages 2 to <18 years with a history of Vaso-Occlusive Crisis (VOC) with or without…
- Trial name
- NCT03474965
- Testing
- Crizanlizumab
- Where
- 35 sites in United States, Belgium and 12 more
- Volunteers
- 117 people
- Sponsor
- Novartis Pharmaceuticals
Sickle Cell Disease
PET Imaging of Vaso-Occlusive Crisis (VOC) in SCD
The purpose of this study is to find objective biomarkers of vaso-occlusion (blood vessel blockage) in people with SCD. Using information from earlier studies and work being done, researchers have developed a strategy to image…
- Trial name
- NCT04925492
- Testing
- Positron Emission Tomography, Cu-64]-LLP2A
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Enrico Novelli
Sickle Cell Disease (SCD)
Exploratory Study on Global Reflexology in Sickle Cell Disease
Sickle cell disease (or sickle cell anemia) is the most common genetic disease in France with 586 children screened in 2019. This chronic disease is characterized by the presence of abnormal Hemoglobin (Hb) S and a deformation of…
- Trial name
- REFLEXODREPANO (NCT06619197)
- Testing
- Global reflexology
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Sickle Cell Crisis
Sickle Cell Improvement: Enhancing Care in the Emergency Department
Sickle cell disease (SCD) is an inherited blood disorder affecting approximately 36,000 children in the United States, approximately 90% of whom are Black.
- Trial name
- SCIENCE (NCT05373771)
- Testing
- Care pathway
- Where
- United States
- Volunteers
- 5,328 people
- Sponsor
- Medical College of Wisconsin
Sickle Cell Disease
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are…
- Trial name
- NCT04657822
- Testing
- Crizanlizumab
- Where
- 31 sites in United States, Belgium and 9 more
- Volunteers
- 130 people
- Sponsor
- Novartis Pharmaceuticals
Sickle Cell Anemia
Pilot Study of Fructose for Sickle Cell Crisis
OBJECTIVES: I. Evaluate the efficacy and tolerability of fructose administered every 6 hours for up to 72 hours to patients in active sickle cell crisis. II.
- Trial name
- NCT00004797
- Testing
- fructose
- Volunteers
- 20 people
- Sponsor
- National Center for Research Resources (NCRR)
Sickle Cell Disease
A Study to Learn About Sickle Cell Disease In Adult Patients
The purpose of this clinical trial is to evaluate the performance of the sickle cell disease (SCD) electronic diary in people with SCD who are on treatment that will change SCD and those not on such a treatment.
- Trial name
- NCT05407805
- Testing
- Electronic Diary
- Where
- 4 sites in United States
- Volunteers
- 98 people
- Sponsor
- Pfizer
Sickle Cell Disease
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
The purpose of this study was to determine whether the investigational drug SelG1 when given to sickle cell disease patients either taking or not taking hydroxyurea was effective in preventing or reducing the occurrence of pain…
- Trial name
- SUSTAIN (NCT01895361)
- Testing
- SelG1
- Where
- 56 sites in United States, Brazil and 1 more
- Volunteers
- 198 people
- Sponsor
- Reprixys Pharmaceutical Corporation
Anemia, Sickle Cell
Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis
Safety and effect of SANGUINATE on Sickle Cell Disease patients experiencing a vaso-occlusive crisis
- Trial name
- NCT02411708
- Testing
- SANGUINATE
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- Prolong Pharmaceuticals
Sickle Cell Disease
Study of a Red Blood Cell Deformability Parameter in Patients With Sickle Cell Disease
Sickle cell disease is the most common genetic disease in the world. It results in the synthesis of an abnormal hemoglobin (HbS) which, in its deoxygenated form, polymerizes and causes structural changes in red blood cells…
- Trial name
- Drepaforme (NCT03977532)
- Testing
- Micro-blood sampling
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Sickle Cell Anemia, Sickle Cell Disease
Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease
This is an open label extension study in subjects with Sickle Cell Disease (SCD) who have completed the double blind Phase 3 study (B5201002).
- Conditions
- Sickle Cell Anemia, Sickle Cell Disease, Sickle Cell Disorders, Pain Crisis
- Trial name
- NCT02433158
- Testing
- Rivipansel
- Where
- 97 sites in United States, Canada
- Volunteers
- 154 people
- Sponsor
- GlycoMimetics Incorporated
Sickle Cell Disease (SCD)
Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
The purpose of this study is to compare the efficacy and safety of 2 doses of crizanlizumab (5.0 mg/kg and 7.5 mg/kg) versus placebo in adolescent and adult sickle cell disease (SCD) patients with history of vaso-occlusive crisis…
- Trial name
- STAND (NCT03814746)
- Testing
- Crizanlizumab (SEG101)
- Where
- 58 sites in United States, Belgium and 19 more
- Volunteers
- 253 people
- Sponsor
- Novartis Pharmaceuticals
Vaso-Occlusive Pain Episode in Sickle Cell Disease, Sickle Cell Disease (SCD)
Low Dose Bolus Ketamine For Use In Sickle Cell Pain Crisis
The goal of this study is to learn if Ketamine works more efficiently, as compared to Opioids, for Sickle Cell Pain The main questions it aims to answer are: Does Ketamine lower the number of times participants need to be…
- Trial name
- NCT07682662
- Testing
- Standardized Low-dose bolus IV Ketamine within 30 minutes of arrival and every 1 hour as needed for max of 3 doses., Standard Care (in control arm)
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- University of Mississippi Medical Center
Sickle Cell
Diastolic Dysfunction in Sickle Cell Disease During Vaso-occlusive Crisis
This study is designed to investigate the presence and absence of abnormal heart muscle contractions during sickle cell crises. You will be asked to do echocardiography during and after your admission to the hospital.
- Trial name
- NCT01683968
- Where
- Saudi Arabia
- Volunteers
- 216 people
- Sponsor
- King Abdullah International Medical Research Center
Sickle Cell Disease
Sleep Apnea in Sickle Cell Disease
Despite the fact that obstructive sleep apnoea (OSA) is highly prevalent in the sickle cell population, studies focusing on the associations of the two diseases and their common pathophysiological mechanisms are scarce.
- Trial name
- DREPAPNEE (NCT03753854)
- Testing
- polysomnography and oxygen saturation exam, calculation of VOC frequency between the first polysomnography and the end of the first year of continuous positive airway pressure treatment, Blood samples
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon